AstraZeneca Chips Away At Seroquel Case

Law360, New York (July 30, 2007, 12:00 AM EDT) -- In the multidistrict litigation alleging its antipsychotic Seroquel causes diabetics, AstraZeneca wants the court to grant it partial judgment based on federal preemption, and to toss another 32 plaintiffs from the case for allegedly failing to submit medical records.

In a memorandum filed Tuesday, the drug company said the plaintiffs' state law failure-to-warn claims alleging inadequate labeling were barred because they conflicted with federal law.

“Indeed, they involve a direct assault on the FDA’s authoritative federal determinations concerning the appropriate diabetes-related warnings that must accompany Seroquel,”...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.